<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="protocol"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="hwp">bmjopen</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28167746</article-id><article-id pub-id-type="pmc">5293990</article-id><article-id pub-id-type="publisher-id">bmjopen-2016-014037</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2016-014037</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Protocol</subject></subj-group></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1683</subject><subject>1727</subject><subject>1731</subject></subj-group></article-categories><title-group><article-title>Randomised controlled trial examining the effect of an outpatient exercise training programme on haemodynamics and cardiac MR parameters of right ventricular function in patients with pulmonary arterial hypertension: the ExPAH study protocol</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0089-8151</contrib-id><name><surname>Chia</surname><given-names>Karen S W</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Faux</surname><given-names>Steven G</given-names></name><xref ref-type="aff" rid="af3">3</xref><xref ref-type="aff" rid="af4">4</xref><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Peter K K</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Holloway</surname><given-names>Cameron</given-names></name><xref ref-type="aff" rid="af4">4</xref><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7404-8144</contrib-id><name><surname>Assareh</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>McLachlan</surname><given-names>Craig S</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kotlyar</surname><given-names>Eugene</given-names></name><xref ref-type="aff" rid="af4">4</xref><xref ref-type="aff" rid="af5">5</xref></contrib></contrib-group><aff id="af1"><label>1</label><institution>University of New South Wales Rural Clinical School</institution>, <addr-line>Coffs Harbour, New South Wales</addr-line>, <country>Australia</country></aff><aff id="af2"><label>2</label><institution>Coffs Harbour Health Campus</institution>, <addr-line>Coffs Harbour, New South Wales</addr-line>, <country>Australia</country></aff><aff id="af3"><label>3</label><addr-line>Sacred Heart Rehabilitation</addr-line>, <institution>St Vincent's Health</institution>, <addr-line>Coffs Harbour, New South Wales</addr-line>, <country>Australia</country></aff><aff id="af4"><label>4</label><institution>University of New South Wales</institution>, <addr-line>Coffs Harbour, New South Wales</addr-line>, <country>Australia</country></aff><aff id="af5"><label>5</label><institution>St Vincent's Hospital Sydney</institution>, <addr-line>Coffs Harbour, New South Wales</addr-line>, <country>Australia</country></aff><aff id="af6"><label>6</label><institution>Mid-North Coast Arthritis Clinic</institution>, <addr-line>Coffs Harbour, New South Wales</addr-line>, <country>Australia</country></aff><aff id="af7"><label>7</label><addr-line>Epidemiology and Health Analytics Department</addr-line>, <institution>Western Sydney Local Health District</institution>, <addr-line>Coffs Harbour, New South Wales</addr-line>, <country>Australia</country></aff><author-notes><corresp><label>Correspondence to</label> Dr Karen SW Chia; <email>Karen.chia@me.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>6</day><month>2</month><year>2017</year></pub-date><volume>7</volume><issue>2</issue><elocation-id>e014037</elocation-id><history><date date-type="received"><day>25</day><month>8</month><year>2016</year></date><date date-type="rev-recd"><day>9</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>5</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bmjopen-2016-014037.pdf"/><abstract><sec><title>Introduction</title><p>Pulmonary hypertension (PH) is a potentially life-threatening condition characterised by elevated pulmonary artery pressure. Early stage PH patients are often asymptomatic. Disease progression is associated with impairment of right ventricular function and progressive dyspnoea. Current guidelines recommend exercise training (grade IIa, level B). However, many questions remain regarding the mechanisms of improvement, intensity of supervision and optimal frequency, duration and intensity of exercise. This study will assess the effect of an outpatient rehabilitation programme on haemodynamics and cardiac right ventricular function in patients with pulmonary arterial hypertension (PAH), a subgroup of PH.</p></sec><sec><title>Methods and analysis</title><p>This randomised controlled trial involves both a major urban tertiary and smaller regional hospital in New South Wales, Australia. The intervention will compare an outpatient rehabilitation programme with a control group (home exercise programme). Participants will be stable on oral PAH-specific therapy. The primary outcome measure will be right ventricular ejection fraction measured by cardiac MRI. Secondary outcomes will include haemodynamics measured by right heart catheterisation, endurance, functional capacity, health-related quality of life questionnaires and biomarkers of cardiac function and inflammation.</p></sec><sec><title>Ethics approval and dissemination</title><p>Ethical approval has been granted by St Vincent's Hospital, Sydney (HREC/14/SVH/341). Results of this study will be disseminated through presentation at scientific conferences and in scientific journals.</p></sec><sec><title>Trial registration number</title><p>ACTRN12615001041549; pre-results.</p></sec></abstract><kwd-group><kwd>Pulmonary hypertension</kwd><kwd>outpatient exercise training</kwd><kwd>cardiac magnetic resonance imaging</kwd><kwd>haemodynamics</kwd></kwd-group></article-meta></front><body><boxed-text position="float" orientation="portrait"><caption><title>Strengths and limitations of this study</title></caption><list list-type="bullet"><list-item><p>To the best of our knowledge, this is the first clinical trial evaluating the effect of an outpatient rehabilitation programme (OP REH) on right ventricular ejection fraction measured by cardiac MRI.</p></list-item><list-item><p>We will also be measuring the effect of an OP REH on haemodynamic parameters as assessed by right heart catheterisation.</p></list-item><list-item><p>The nature of the OP REH reflects &#x02018;real-world&#x02019; conditions generalisable to routine clinical practice (1&#x02005;hour, twice weekly, for 12&#x02005;weeks).</p></list-item><list-item><p>Although participants are not blinded to their allocated treatment group, all study personnel are blinded.</p></list-item><list-item><p>The short follow-up period for this study (6&#x02005;months) is a limitation; however, we were limited by budget constraints.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p>Pulmonary hypertension (PH) is a condition characterised by elevated pulmonary arterial pressure (PAP), and is associated with fatigue, syncope, angina and progressive exertional dyspnoea. It is defined as a mean resting pulmonary arterial pressure (mPAP) of &#x02265;25&#x02005;mm&#x02005;Hg, measured by right heart catheterisation (RHC).<xref rid="R1" ref-type="bibr">1</xref> PH is characterised by vascular remodelling, with a consequent increase in PAP, resulting in increased right ventricular afterload.<xref rid="R2" ref-type="bibr">2</xref>
<xref rid="R3" ref-type="bibr">3</xref> The ability of the right ventricle to adapt to the increased right-sided afterload is key to prognosis.<xref rid="R3" ref-type="bibr">3</xref>
<xref rid="R4" ref-type="bibr">4</xref> Patients with PH generally have a poor prognosis<xref rid="R5" ref-type="bibr">5</xref> in particular patients with pulmonary arterial hypertension (PAH). Median survival of patients with PAH is between 2 and 3&#x02005;years.<xref rid="R6" ref-type="bibr">6</xref> Underlying aetiology is an important prognostic factor, with scleroderma-related PAH (a subtype of PAH) having a worse prognosis.<xref rid="R7" ref-type="bibr">7&#x02013;9</xref></p><p>PAH is a precapillary subtype of PH, with additional haemodynamic criteria of pulmonary artery wedge pressure &#x02264;15&#x02005;mm&#x02005;Hg and pulmonary vascular resistance (PVR) &#x0003e;3 Wood units.<xref rid="R10" ref-type="bibr">10</xref> The focus of this study is patients with PAH.</p><p>Exercise has not previously been recommended in patients with PAH, particularly in patients with more advanced disease, due to safety concerns.<xref rid="R11" ref-type="bibr">11</xref> However, exercise training has been shown to be safe in patients with PAH,<xref rid="R12" ref-type="bibr">12</xref> and current European guidelines recommend exercise training and rehabilitation in experienced centres for patients with PAH who are clinically stable, on optimal pharmacological treatment (grade IIa, level B).<xref rid="R1" ref-type="bibr">1</xref></p><p>The first major study involving patients with PH (patients with PAH and chronic thromboembolic PH) showed that exercise was beneficial. Thirty participants were randomised to either exercise training or a control group (education on healthy nutrition, muscular relaxation).<xref rid="R13" ref-type="bibr">13</xref> The exercise training group underwent an intensive 3-week inpatient programme of a minimum of 2&#x02005;hours/day of exercise (strength and endurance training, and respiratory muscle exercises) and education (healthy nutrition, muscle relaxation). This was followed by a 12-week home exercise programme (HEP). The exercise training group had a marked improvement in 6&#x02005;min walk test (6MWT) distance compared with the control group, with mean between-group difference of 111&#x02005;m (95% CI 65 to 139; p&#x0003c;0.001). Quality of life (QOL), measured by the Short Form-36 (SF-36),<xref rid="R14" ref-type="bibr">14</xref> also improved in the exercise training group.</p><p>Seventeen more studies examining the effect of exercise training on PH have been published up to June 2016, since the above landmark study in 2006. These studies are generally small in size, and are of varying quality (only six randomised controlled trials (RCTs)).<xref rid="R15" ref-type="bibr">15</xref> Several studies<xref rid="R12" ref-type="bibr">12</xref>
<xref rid="R16" ref-type="bibr">16&#x02013;22</xref> using the Mereles <italic>et al</italic><xref rid="R13" ref-type="bibr">13</xref> inpatient protocol (described previously) reported improvement in a number of outcome measures, including 6MWT and QOL. The largest RCT of these studies (n=87), recently published by Ehlken <italic>et al</italic><xref rid="R20" ref-type="bibr">20</xref> has further added to the current body of knowledge by showing that exercise training using the Mereles <italic>et al</italic> inpatient protocol improved haemodynamics.</p><p>However, it is difficult to replicate the intensity of this inpatient exercise programme in routine clinical practice due to limited resources and personnel. In the Australian context, the Mereles <italic>et al</italic> protocol is not currently widely available due to cost constraints. Cardiac and pulmonary rehabilitation programmes in Australia are usually run by public hospital outpatient services or community settings, two to three times per week at minimal or no cost to patients.<xref rid="R23" ref-type="bibr">23</xref>
<xref rid="R24" ref-type="bibr">24</xref></p><p>A more achievable programme of exercising two to three times per week for 1&#x02005;hour per session may still have beneficial effects on walk distance,<xref rid="R25" ref-type="bibr">25&#x02013;30</xref> peak oxygen consumption,<xref rid="R26" ref-type="bibr">26</xref> QOL, self-reported symptoms,<xref rid="R27" ref-type="bibr">27</xref> fatigue and activity levels.<xref rid="R28" ref-type="bibr">28</xref> We have therefore designed this study with &#x02018;real-world&#x02019; conditions in mind to ensure broad generalisability. Given anxiety and depression are important factors associated with dyspnoea,<xref rid="R31" ref-type="bibr">31</xref> we have chosen to include a structured psychology intervention as part of the outpatient rehabilitation programme (OP REH) to address this.</p><sec id="s1a"><title>Hypotheses</title><p>We hypothesise that an OP REH (involving endurance training, respiratory muscle training (RMT) and structured psychology intervention) will have beneficial effects on cardiac remodelling (reflected in an improvement in right ventricular ejection fraction (RVEF)), haemodynamics, strength and endurance, and QOL. We hypothesise that these benefits will be due to improved right-sided cardiac function as determined by an improvement in RVEF.</p><p>The key difference of this study compared with previous studies is the inclusion of cardiac MRI (cMRI) and haemodynamics, as well as other secondary outcome measures (as listed below) that will help elucidate the mechanism of improvement of exercise training. If secondary outcome measures increase despite no improvement in RVEF, this would suggest that other mechanisms are responsible for the improvement in exercise capacity.</p></sec><sec id="s1b"><title>Objectives</title><p>To assess whether the &#x02018;real-world&#x02019; frequency of OP REH available in Australia (ie, 1&#x02005;hour, twice weekly, for 12&#x02005;weeks) has a beneficial effect on:
<list list-type="order"><list-item><p>Cardiac function (RVEF and volume as assessed by cMRI);</p></list-item><list-item><p>Haemodynamics, measured by RHC, the gold standard for assessing PAH;<xref rid="R10" ref-type="bibr">10</xref></p></list-item><list-item><p>Dominant hand grip strength (DHGS) and exercise capacity (6MWT);</p></list-item><list-item><p>Function and QOL (measured by questionnaires: the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), Depression and Anxiety Severity Scale (DASS21), Lawton's Instrumental Activities of Daily Living (IADL);</p></list-item><list-item><p>Serum biomarkers of cardiac function and inflammation (N terminal pro b-type natriuretic peptide (NT-proBNP), interleukin (IL-6));</p></list-item><list-item><p>Lung function (vital capacity).</p></list-item></list></p></sec></sec><sec id="s2"><title>Methods and analysis</title><sec id="s2a"><title>Study design</title><p>The study is designed as a dual-centre, investigator-blinded clinical trial to compare the efficacy of an OP REH versus a HEP. Participants will be randomised in a 1:1 ratio. The exercise intervention will occur for 12&#x02005;weeks.</p></sec><sec id="s2b"><title>Study population</title><p>Study participants will be identified by cardiologists and rheumatologists during the course of routine care at St Vincent's Hospital, Sydney, Australia, and from the Coffs Harbour PAH Clinic, an outpatient clinic affiliated with the Coffs Harbour Health Campus (regional hospital). Participants must fulfil all inclusion criteria (<xref ref-type="table" rid="BMJOPEN2016014037TB1">table 1</xref>). Exclusion criteria are outlined in <xref ref-type="table" rid="BMJOPEN2016014037TB2">table 2</xref>. We have excluded WHO Class IV participants, due to safety concerns regarding exercising these participants in an outpatient setting.</p><table-wrap id="BMJOPEN2016014037TB1" orientation="portrait" position="float"><label>Table&#x000a0;1</label><caption><p>Inclusion criteria</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Criteria</th><th align="left" colspan="2" rowspan="1">Characteristics of eligible participants<hr/></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1.</td><td colspan="2" rowspan="1">Male and female patients aged &#x02265;18&#x02005;years</td></tr><tr><td rowspan="3" colspan="1">2.</td><td colspan="2" rowspan="1">PAH diagnosed by RHC (at any time prior to baseline) with the following parameters:<xref rid="R32" ref-type="bibr">32</xref></td></tr><tr><td rowspan="1" colspan="1">i.</td><td rowspan="1" colspan="1">Resting mPAP&#x02265;25&#x02005;mm&#x02005;Hg, and</td></tr><tr><td rowspan="1" colspan="1">ii.</td><td rowspan="1" colspan="1">Resting PCWP or LVEDP&#x02264;15&#x02005;mm&#x02005;Hg</td></tr><tr><td rowspan="1" colspan="1">3.</td><td colspan="2" rowspan="1">Stable PAH-specific medication in the preceding 3&#x02005;months</td></tr><tr><td rowspan="1" colspan="1">4.</td><td colspan="2" rowspan="1">Female participants of childbearing potential must have a negative pregnancy test and agree to use contraception for study duration.</td></tr></tbody></table><table-wrap-foot><fn><p>LVEDP, left ventricular end diastolic pressure; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RHC, right heart catheterisation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="BMJOPEN2016014037TB2" orientation="portrait" position="float"><label>Table&#x000a0;2</label><caption><p>Exclusion criteria for the ExPAH study</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Criteria</th><th align="left" rowspan="1" colspan="1">Characteristics of ineligible participants</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1.</td><td rowspan="1" colspan="1"><italic>General exclusion criteria</italic>:
<list list-type="bullet"><list-item><p>Pregnancy</p></list-item><list-item><p>Presence of cognitive impairment and/or neuromuscular weakness of sufficient severity to prevent participation in exercise classes</p></list-item><list-item><p>Non-primary English language limiting ability to comply with exercise classes</p></list-item><list-item><p>WHO Functional Class IV</p></list-item><list-item><p>enrolled in a formal exercise training programme within preceding 12 weeks</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">2.</td><td rowspan="1" colspan="1"><italic>PAH-specific</italic>:
<list list-type="bullet"><list-item><p>Change in PAH medication within preceding 3&#x02005;months</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">3.</td><td rowspan="1" colspan="1"><italic>Presence of significant cardiac disease, including</italic>:
<list list-type="bullet"><list-item><p>Unstable angina pectoris (ie, chest pain not controlled with medications)</p></list-item><list-item><p>Unstable CCF requiring escalation of medication within preceding 3&#x02005;months</p></list-item><list-item><p>Exercise-induced arrhythmias such as atrial fibrillation, ventricular tachycardia</p></list-item><list-item><p>Hypertrophic obstructive cardiomyopathy</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">4.</td><td rowspan="1" colspan="1"><italic>Patients unable to undergo MRI</italic>:
<list list-type="bullet"><list-item><p>Presence of impaired renal function (eGFR&#x0003c;60&#x02005;mL/min) due to a possible adverse event with intravenous gadolinium contrast</p></list-item><list-item><p>In situ pacemaker or implantable cardiac defibrillator</p></list-item><list-item><p>Other metal or electronic implants affected by a magnetic field</p></list-item><list-item><p>Shrapnel injuries</p></list-item><list-item><p>Previous eye injury involving metal fragments</p></list-item><list-item><p>Metal clips in cerebral blood vessels</p></list-item><list-item><p>Joint replacement within 3&#x02005;months</p></list-item><list-item><p>Previous serious adverse event to MRI gadolinium contrast agents</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn><p>CCF, congestive cardiac failure; eGFR, estimated glomerular filtration rate; PAH, pulmonary arterial hypertension.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Recruitment, randomisation and allocation concealment</title><p>The ExPAH study has been designed in line with the Consolidated Standards of Reporting Trials (CONSORT) statement.<xref rid="R33" ref-type="bibr">33</xref> The study protocol is outlined in <xref ref-type="fig" rid="BMJOPEN2016014037F1">figure 1</xref>.</p><fig id="BMJOPEN2016014037F1" orientation="portrait" position="float"><label>Figure&#x000a0;1</label><caption><p>ExPAH protocol: enrolment, allocation, follow-up and analysis. Participants are screened for eligibility. If eligible, once informed consent obtained, participants are then randomised to control group (home exercise) or intervention group (outpatient rehabilitation exercise programme). Participants are reviewed at weeks 12 and 26; participants who have not completed the required attendance (&#x0003e;70%) are recorded. Analysis of results will be both by intention-to-treat and per protocol methods. OP REH, outpatient rehabilitation programme.</p></caption><graphic xlink:href="bmjopen2016014037f01"/></fig><p>All eligible participants will have the aims, methods and potential adverse events explained to them by the study investigators prior to signing informed consent. Recruitment will occur until sample size requirements are met (anticipated duration of recruitment 1&#x02013;2&#x02005;years).</p><p>Randomisation will occur after screening (see below) and will be carried out using a minimisation scheme to achieve balance by research site and presence of connective tissue disease-associated PAH, as this particular cohort of patients with PAH has a worse prognosis<xref rid="R7" ref-type="bibr">7</xref> as mentioned previously. Randomisation will be carried out by an independent biostatistician using a customised programme for minimisation (QMinim).<xref rid="R34" ref-type="bibr">34</xref> The participant will be allocated to either control (HEP) or the intervention (OP REH). Administrative staff not involved with the project will inform participants via mail regarding their allocation group.</p><p>Participants will not be blinded to the intervention. However, assessments and data analysis will be carried out by blinded investigators.</p></sec><sec id="s2d"><title>Outcome measures</title><sec id="s2d1"><title>Cardiac MRI</title><p>cMRI was chosen as it is the &#x02018;gold standard&#x02019; for assessing right ventricular structure and function.<xref rid="R35" ref-type="bibr">35</xref> cMRI studies will be performed using a single 1.5 Tesla (T) MR system (Philips) and 3T (Siemens Healthcare, Germany). A complete stack of short axis images will be obtained during breath-hold and cardiac gating for cine, and late gadolinium enhancement (LGE) imaging. LGE imaging will be performed as previously described<xref rid="R36" ref-type="bibr">36</xref> using a T1-weighted phase-sensitive inversion recovery sequence &#x0223c;8&#x02005;min after intravenous administration of a contrast agent (Gadoterate meglumine&#x02013;Gd-DOTA, Dotarem, Guerbet LLC, France; 0.15&#x02005;mmol/kg body weight). Imaging parameters will be the same as previously published.<xref rid="R37" ref-type="bibr">37</xref> All cMRIs will be analysed using CMR42 software (Canada), as previously described,<xref rid="R38" ref-type="bibr">38</xref> by the investigators blinded to participant randomisation group.</p></sec><sec id="s2d2"><title>Right heart catheterisation</title><p>Standard haemodynamic parameters measured by RHC<xref rid="R10" ref-type="bibr">10</xref> were chosen as a secondary outcome measure based on the known impairments in PAH and previous noted improvements with inpatient rehabilitation in the cardiac index, mPAP and PVR.<xref rid="R20" ref-type="bibr">20</xref> RHC will be performed according to a standard protocol<xref rid="R10" ref-type="bibr">10</xref> by trained cardiologists who are blinded to the participant's randomisation group.</p></sec><sec id="s2d3"><title>Frailty and exercise capacity</title><p>As skeletal muscle weakness is a known complication of PH,<xref rid="R39" ref-type="bibr">39&#x02013;43</xref> DHGS will also be included as a secondary end point. In addition, decreased hand grip strength (HGS) has been noted to be associated with increased all-cause mortality.<xref rid="R44" ref-type="bibr">44</xref> DHGS will be measured by a physiotherapist blinded to the participant's randomisation group (using a Jamar Hydraulic Hand Dynamometer, Sammons Preston, Canada).</p><p>Exercise capacity, as measured by 6MWT, has been widely used as an outcome measure in trials of exercise training and pharmacological management of PAH. This study will assess whether the increase in 6MWT seen with previous trials<xref rid="R45" ref-type="bibr">45</xref>
<xref rid="R46" ref-type="bibr">46</xref> will be able to be reproduced with an outpatient programme. Exercise capacity will be measured by a trained assessor (who is blinded to the study randomisation). All participants will be assessed undertaking two supervised 6MWTs separated by a rest of at least 30&#x02005;min, in accordance with European Respiratory Society/American Thoracic Society technical standards.<xref rid="R47" ref-type="bibr">47</xref></p></sec><sec id="s2d4"><title>Questionnaires of function and QOL</title><p>Mental health disorders are very common, with &#x0223c;35% of patients with PAH suffering depression and anxiety.<xref rid="R48" ref-type="bibr">48</xref> Depression and anxiety in patients with PAH is associated with reduced QOL.<xref rid="R49" ref-type="bibr">49</xref> While reduction in health-related QOL is well documented in PAH, the focus of these studies have been on physical function, mental health and social isolation,<xref rid="R50" ref-type="bibr">50</xref> with less emphasis on activities of daily living. We have therefore included a short questionnaire of daily activities (Lawton's IADL) which looks at other household tasks/roles.<xref rid="R51" ref-type="bibr">51</xref> All study participants will complete three questionnaires at baseline, 12 and 26 weeks:
<list list-type="roman-upper"><list-item><p>The CAMPHOR<xref rid="R52" ref-type="bibr">52</xref>&#x02014;a PH-specific QOL outcome measure validated in the Australian population;<xref rid="R53" ref-type="bibr">53</xref></p></list-item><list-item><p>Lawton's IADL<xref rid="R54" ref-type="bibr">54</xref>&#x02014;a measure of impairment of daily activities;</p></list-item><list-item><p>DASS<xref rid="R55" ref-type="bibr">55</xref>&#x02014;to assess concurrent depression and anxiety.</p></list-item></list></p></sec><sec id="s2d5"><title>Blood test markers of cardiac function and inflammation</title><p>N-terminal fragment (NT-proBNP) and IL-6 were included as outcome measures for their prognostic value in PH.<xref rid="R56" ref-type="bibr">56</xref>
<xref rid="R57" ref-type="bibr">57</xref> NT-proBNP is the inactive N-terminal component produced when the ventricles secrete a prohormone, pro-BNP that is cleaved into an active form (BNP) and an inactive fragment (NT-proBNP).<xref rid="R58" ref-type="bibr">58</xref> NT-proBNP is a clinically useful and minimally invasive test that correlates well with survival. NT-proBNP values &#x0003e;1400 to 1700 were associated with a poorer prognosis.<xref rid="R59" ref-type="bibr">59</xref> IL-6 is a marker of inflammation that adds further prognostic information in patients with PAH.<xref rid="R57" ref-type="bibr">57</xref> Blood samples will be collected at baseline, weeks 12 and 26 follow-up visits in serum separator tubes for analysis.</p></sec><sec id="s2d6"><title>Lung function</title><p>Respiratory muscle weakness is a known association with PAH.<xref rid="R60" ref-type="bibr">60</xref>
<xref rid="R61" ref-type="bibr">61</xref> A previous study of inspiratory muscle training (IMT) in patients with PAH has demonstrated significant improvements in respiratory muscle strength, functional capacity, and dyspnoea and fatigue perception.<xref rid="R30" ref-type="bibr">30</xref> Vital capacity is useful for monitoring respiratory muscle weakness.<xref rid="R62" ref-type="bibr">62</xref> Therefore, all participants will undergo vital capacity testing to ascertain whether OP REH improves respiratory muscle weakness. We did not include direct measures of respiratory muscle strength (maximum inspiratory pressure and maximum expiratory pressure) due to financial constraints and safety concerns in this population.</p></sec></sec><sec id="s2e"><title>Assessment</title><p>All participants will undergo the following assessments:</p><sec id="s2e1"><title>The medical screening visit</title><p>Participants will have eligibility reviewed, demographics (age, gender, aetiology of PAH), WHO Functional PH Class, medical history, physical examination and informed consent (if eligible) documented. Eligible participants will undergo cMRI, RHC, lung function tests (vital capacity) and venepuncture for cardiac markers (NT-proBNP and IL-6). Candidates who fail to meet inclusion criteria, or fulfil exclusion criteria will have the reason for study ineligibility documented.</p></sec><sec id="s2e2"><title>Baseline visit</title><p>Participants will return for the baseline visit to review results. Participants will also have a separate visit with a trained assessor (who is blinded to the study randomisation) to undergo two supervised 6MWTs separated by a rest of at least 30&#x02005;min, in accordance with international guidelines.<xref rid="R47" ref-type="bibr">47</xref> DHGS will be recorded, and participants will complete QOL and function questionnaires as described previously. Participants will then be randomised as outlined above.</p></sec><sec id="s2e3"><title>Visit 1 (week 12&#x02013;14)</title><p>Participants will undergo medical review including physical examination at completion of the intervention period after week 12. Adverse events will be recorded, and any clinical episodes (change in PAH-specific medication or hospitalisation secondary to PAH) will be documented. Participants will undertake two supervised 6MWTs by a blinded assessor, have DHGS measured and complete the three study questionnaires, as before. Participants will also undergo cMRI, RHC, lung function tests and venepuncture for cardiac markers (NT-proBNP and IL-6).</p></sec><sec id="s2e4"><title>Visit 2 (week 26)</title><p>Participants will undergo medical review, including physical examination. Any adverse events will be recorded, and any clinical episodes (change in PAH-specific medication or hospitalisation secondary to PAH) will be documented. Participants will undertake two supervised 6MWTs by a blinded assessor as before. Participants will undergo venepuncture for serum cardiac and inflammatory biomarkers. Participants will have assessment of DHGS and complete the three QOL questionnaires as in visit 1.</p></sec></sec><sec id="s2f"><title>Interventions</title><p>Exercise:</p><sec id="s2f1"><title>Intervention (OP REH)</title><p>All participants randomised to this group will undertake physiotherapist-supervised, outpatient hospital based, group exercise training for 1&#x02005;hour/week, twice weekly, for 12&#x02005;weeks, with the following components:
<list list-type="bullet"><list-item><p>Endurance training</p></list-item><list-item><p>Twenty minutes of lower limb endurance training by walking or cycling. Participants will start at a speed of 60% of the speed of their 6MWT. If a participant chooses to cycle instead of walk, then intensity will be based on an initial level of light-to-somewhat hard exertion using the Borg Rating of Perceived Exertion (RPE)<xref rid="R63" ref-type="bibr">63</xref> at a level of 12&#x02013;13).</p></list-item><list-item><p>If participants are unable to complete 20&#x02005;min of lower limb endurance training, they will increase duration by 5&#x02005;min each time until able to complete 20&#x02005;min total. During the exercise training class, participants' heart rate (HR) will be monitored via portable HR and oxygen saturations machine. HR will be kept &#x0003c;120&#x02005;bpm, as per current recommendations.<xref rid="R64" ref-type="bibr">64</xref> Participants' oxygen saturations (O<sub>2</sub> sats) will be kept &#x0003e;88% on room air, as per recent international guidelines.<xref rid="R65" ref-type="bibr">65</xref></p></list-item><list-item><p>Progression of training will occur by increasing the treadmill gradient by 1% on each visit, or increase speed by 5% each week, as tolerated, maintaining an intensity of 12&#x02013;13 on Borg RPE, if HR and O<sub>2</sub> sats are able to be maintained within the range as stated above.</p></list-item><list-item><p>Respiratory muscle training</p></list-item><list-item><p>During the exercise training group sessions, all participants will undergo RMT taught by a physiotherapist. Training will involve education at the first intervention visit regarding breathing techniques to manage symptoms (pursed-lip breathing and diaphragmatic breathing). All subsequent sessions will include 10&#x02005;min of supervised IMT using individual IMT devices (threshold IMT positive inspiratory pressure device, Phillips). Ideally, maximal inspiratory pressure (MIP) should be measured by formal lung function tests. However, these tests are expensive, and may be difficult for some patients to undertake. Even without formal MIP, IMT training can be prescribed, using the Borg RPE at a target of RPE 12&#x02013;13.<xref rid="R66" ref-type="bibr">66</xref> The benefit from IMT is seen at levels as low as 30% of MIP.<xref rid="R67" ref-type="bibr">67</xref> Training at a Borg RPE of 12&#x02013;13 correlates with &#x0223c;40% of MIP.<xref rid="R66" ref-type="bibr">66</xref></p></list-item><list-item><p>Strength training</p></list-item><list-item><p>To achieve benefit, strength training needs to occur at repetitions of 50&#x02013;80% of the one repetition maximum (1RM), at least two to three times per week.<xref rid="R65" ref-type="bibr">65</xref> If the 1RM is difficult to obtain, we will alternatively use a weight that the participant can only lift 10 times.<xref rid="R23" ref-type="bibr">23</xref> Strength training of the upper limbs and lower limbs will occur twice weekly at the supervised training sessions for a total of 20&#x02005;min. Initial intensity will be based on the 1RM, and increased by 10% of load once the participant is able to perform two sets of 10 repetitions on two consecutive training sessions.<xref rid="R68" ref-type="bibr">68</xref> Upper limb exercises will include dumbbell row, seated chest press and lateral arm raise.</p></list-item><list-item><p>Lower limb strength training exercises will include step ups and sit to stands.</p></list-item><list-item><p>HEP at week 3</p></list-item><list-item><p>Participants will be given a HEP, consisting of instructions to walk 3&#x02005;days/week for 30&#x02005;min total per day, in addition to attending the twice weekly classes with the physiotherapist. Participants will also be provided with their own IMT device as described above, and given written instructions on undertaking IMT training for 30&#x02005;min per day for 5&#x02005;days/week. Participants who desaturate to &#x0003c;88% on room air (RA) while exercising (as determined during their exercise class) will be given a modified HEP of interval training. This will consist of advice to walk for 1&#x02005;min then 1&#x02005;min of rest, initially for 15&#x02013;20&#x02005;min for the first four sessions, then increasing to 45&#x02013;60&#x02005;min (including rest time).<xref rid="R69" ref-type="bibr">69</xref> All participants will be advised to cease their exercise programme until review by their physiotherapist if they become symptomatic (feel unwell, dizziness, light headedness, dyspnoea).</p></list-item></list></p></sec><sec id="s2f2"><title>Control group (HEP)</title><p>Participants randomised to the HEP will be given written material recommending a walking programme for 5&#x02005;days/week for 30&#x02005;min total per day. This can be broken up into smaller sessions per day to make it more achievable (eg, walking for 10&#x02005;min, three times per day). Advice will be provided on how to stay motivated, as well as a diary to record exercise undertaken.</p></sec></sec><sec id="s2g"><title>Psychology intervention</title><sec id="s2g1"><title>Intervention group (OP REH)</title><p>The OP REH group will also have standardised individual counselling support for three sessions (20&#x02005;min sessions) via telephone by the study psychologist during the 12-week intervention. This will be structured as follows:</p><p><italic>Session 1</italic>: education on how to manage hyperventilation and anxiety during breathlessness.<xref rid="R70" ref-type="bibr">70</xref></p><p><italic>Session 2</italic>: structured cognitive&#x02013;behavioural therapy to manage dyspnoea. This will involve education and challenging of catastrophic thoughts.<xref rid="R71" ref-type="bibr">71</xref></p><p><italic>Session 3</italic>: skills training. This will involve education and practice in progressive muscle relaxation.<xref rid="R72" ref-type="bibr">72</xref> Participants will be given written instructions (as well as verbal instructions) regarding how to do this.</p></sec><sec id="s2g2"><title>Control group</title><p>The control group will not receive any psychology input as part of the study protocol.</p></sec></sec><sec id="s2h"><title>Adherence</title><p>The intervention group will have attendance at each exercise session recorded by the treating physiotherapist. The intervention and the control groups will both be given a diary to record their home activity level. Participants who have completed &#x0003e;70% of sessions (including self-documented HEP) will be deemed to have completed the programme.</p></sec><sec id="s2i"><title>Withdrawal criteria</title><p>Participants may voluntarily withdraw from the study at any time, or if they experience a serious adverse event (SAE) that is associated with an exercise session (during or up to 24&#x02005;hours postintervention). An SAE is defined as an untoward medical occurrence that results in any of the following: death, a life-threatening event, inpatient hospitalisation, persistent or significant disability/incapacity, and a condition requiring medical or surgical intervention. Other adverse events (defined as any unfavourable and unintended sign, symptom or disease temporally associated with any of the investigations or the intervention), such as failure to progress according to protocol, syncope and presyncope will also be recorded. Participants may also be withdrawn if the designated blinded medical assessor at the participant's site deems it unsafe for them to continue with the study.</p></sec><sec id="s2j"><title>Data collection, confidentiality, storage and archiving of study documents</title><p>All personnel involved in data collection will be blinded. Study documents will be de-identified and stored for 15&#x02005;years, as per protocol for non-clinical trial notification (CTN) interventional studies.<xref rid="R73" ref-type="bibr">73</xref> Data will be stored electronically, on double password-protected computers. Data on paper (the Clinical Research File) will be stored in a locked, secure office. The principal investigators will have access to the final trial data set.</p></sec><sec id="s2k"><title>Analysis of outcome measures</title><p>The primary outcome measure is the absolute change (increase) in RVEF from baseline to visit 1, assessed by cMRI.</p><p>Secondary outcome measures include:
<list list-type="alpha-upper"><list-item><p>Absolute change in other parameters on cMRI from baseline to visit 1. These parameters include stroke volume, right ventricular end systolic volume, right ventricular end diastolic volume, right ventricular mass, left ventricular end systolic volume, left ventricular end diastolic volume and left ventricular mass, cross-sectional septum thickness at the level of the papillary muscle.</p></list-item><list-item><p>Absolute change in haemodynamics measured by RHC from baseline to visit 1, including PVR, cardiac output, mean right atrial pressure, mPAP and systemic vascular resistance.</p></list-item><list-item><p>Absolute change in measures of strength and exercise capacity from baseline to visit 1 and 2, including 6MWT, muscle strength testing (DHGS).</p></list-item><list-item><p>Measures of function and QOL scores at baseline, visit 1 and 2, including the CAMPHOR, Lawton's IADL and DASS21.</p></list-item><list-item><p>Blood test markers of cardiac function and inflammation (NT-proBNP and IL-6).</p></list-item><list-item><p>Lung function tests (vital capacity).</p></list-item></list></p></sec><sec id="s2l"><title>Statistical considerations</title><sec id="s2l1"><title>Sample size calculation</title><p>Power calculations are based on comparison of randomised arms achieving the primary outcome of an increase in RVEF. We consider a 5% absolute excess increase in RVEF, measured by cMRI, for the intervention group compared with the control group as the desired clinically important effect to be detected.<xref rid="R74" ref-type="bibr">74</xref> This increase corresponds to at least a 14% improved outcome for the intervention group, in conjunction with no improvement in the control group within a population of patients with an average RVEF of 35%.<xref rid="R75" ref-type="bibr">75</xref></p><p>Although measurement of RVEF by cMRI has high reproducibility,<xref rid="R76" ref-type="bibr">76</xref> we will minimise bias by conducting analyses of cMRI by the same investigator.<xref rid="R75" ref-type="bibr">75</xref>
<xref rid="R76" ref-type="bibr">76</xref> In our power calculation, we have incorporated 6% SD for both SD of changes compared with baseline and measurement variability at the time of follow-up, reported by Addetia <italic>et al</italic>.<xref rid="R75" ref-type="bibr">75</xref> Using two-sided normal test with a significance level of 5% based on clinical equivalent design<xref rid="R77" ref-type="bibr">77</xref> and potential 10% drop off, 26 patients in each arm are required to detect a 5% excess increased RVEF associated with intervention versus control group with a power of 80%. Our power calculation is comparable to other published papers calculating sample size required for cMRI and RVEF trials.<xref rid="R62" ref-type="bibr">62</xref>
<xref rid="R76" ref-type="bibr">76</xref></p></sec><sec id="s2l2"><title>Analysis populations</title><p>The primary and secondary end points A&#x02013;D will be assessed in the intention-to-treat study population, defined as all participants who are randomised according to their randomised arm. In this analysis, participants missing their primary end point data for any reason will be imputed as failures for binary end points, and will have their previous observation carried forward for continuous end points. The primary end point will be analysed as per protocol analysis (this excludes participant data from the time at which they cease their randomised intervention). Secondary end points E&#x02013;G will be assessed in a per protocol population, using available data.</p></sec><sec id="s2l3"><title>Results analysis</title><p>Results will be analysed using STATA V.13 (StataCorp), SAS (Cary, North Carolina, USA) or R V.3.2.2 (R Core Team, Austria). Primary outcome and participant continuous characteristics will be compared between two randomised arms using a t-test or Wilcoxon test, as appropriate. Binary end points and categorical characteristics will be compared using a &#x003c7;<sup>2</sup> or Fisher's exact test as appropriate. In case of differences in baseline characteristics across arms, adjusted characteristics effects on outcomes and their changes over time points will be evaluated using generalised linear models or non-parametric equivalents. Adherence to intervention will be described based on data in the participant diary. Participants will be deemed to have completed the intervention if their total (attendance and self-recorded home diary) adherence is &#x0003e;70%. For QOL questionnaire components with categorical cut-offs (the DASS21) the proportion of participants in each category at each visit will be compared by randomised arm. As the CAMPHOR and Lawton's IADL are ordinal scales, ordinal-based tests and regression modelling or non-parametric equivalents will be used.</p></sec></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>To the best of our knowledge, the ExPAH study will be the first RCT to measure both haemodynamics and cMRI parameters. It is hypothesised that the data obtained will define reverse cardiac remodelling (defined by an increase in RVEF) as a mechanism that is important in the improvement observed in patients with PAH following exercise training.</p><p>Secondary outcome measures will also measure the effect of an OP REH on HGS and exercise capacity, QOL, depression, stress and anxiety, cardiac biomarkers and vital capacity. While these outcomes are all of clinical relevance, such a comprehensive data set requires significant time commitment by participants. This may limit recruitment, adherence and attendance.</p><sec id="s3a"><title/><sec id="s3a1"><title>Pragmatic approach</title><p>There was some debate regarding which exercise components should be included. However, we were determined to design an exercise intervention with broad generalisability within a &#x02018;real-world&#x02019; setting of limited therapy time and resources.</p><p>The results of this study will assist in guiding clinical practice regarding the type of exercise, duration and frequency that is of benefit in patients with PAH.</p></sec></sec></sec></body><back><ack><p>The authors wish to thank Professor Stephen Kerr (Kirby Institute, New South Wales, Australia) for his assistance with the Statistics section.</p></ack><fn-group><fn><p><bold>Contributors:</bold> KSWC conceived the study, coordinated its design and drafted the manuscript. SGF and EK had significant input into the study protocol. PKKW, CSM, SGF and EK read and were involved in critical appraisal and revision of the manuscript. CH provided MRI expertise. HA provided statistical expertise. All authors approved the final manuscript prior to submission.</p></fn><fn><p><bold>Funding:</bold> KSWC has received grants from the Mid-North Coast Local Health District and the Royal Australasian College of Physicians for this study. KSWC and EK have received an unrestricted educational grant from Actelion. Actelion have reviewed the manuscript. However, final content and design is exclusively retained by the authors.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn><p><bold>Ethics approval:</bold> St Vincent's Hospital Research and Ethics Committee.</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gali&#x000e8;</surname><given-names>N</given-names></name>, <name><surname>Humbert</surname><given-names>M</given-names></name>, <name><surname>Vachiery</surname><given-names>JL</given-names></name><etal/></person-group>
<article-title>2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Heart J</source>
<year>2016</year>;<volume>37</volume>:<fpage>67</fpage>&#x02013;<lpage>119</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehv317">doi:10.1093/eurheartj/ehv317</ext-link><pub-id pub-id-type="pmid">26320113</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>LS</given-names></name></person-group>
<article-title>Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease</article-title>. <source>Eur Respir Rev</source>
<year>2011</year>;<volume>20</volume>:<fpage>236</fpage>&#x02013;<lpage>42</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09059180.00006711">doi:10.1183/09059180.00006711</ext-link><pub-id pub-id-type="pmid">22130816</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peacock</surname><given-names>AJ</given-names></name>, <name><surname>Vonk Noordegraaf</surname><given-names>A</given-names></name></person-group>
<article-title>Cardiac magnetic resonance imaging in pulmonary arterial hypertension</article-title>. <source>Eur Respir Rev</source>
<year>2013</year>;<volume>22</volume>:<fpage>526</fpage>&#x02013;<lpage>34</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09059180.00006313">doi:10.1183/09059180.00006313</ext-link><pub-id pub-id-type="pmid">24293468</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>KM</given-names></name>, <name><surname>Kim</surname><given-names>NH</given-names></name>, <name><surname>Rubin</surname><given-names>LJ</given-names></name></person-group>
<article-title>The right ventricle in pulmonary hypertension</article-title>. <source>Coron Artery Dis</source>
<year>2005</year>;<volume>16</volume>:<fpage>13</fpage>&#x02013;<lpage>18</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00019501-200502000-00003">doi:10.1097/00019501-200502000-00003</ext-link><pub-id pub-id-type="pmid">15654194</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corciova</surname><given-names>FC</given-names></name>, <name><surname>Arsenescu-Georgescu</surname><given-names>C</given-names></name></person-group>
<article-title>Prognostic factors in pulmonary hypertension</article-title>. <source>Maedica (Buchar)</source>
<year>2012</year>;<volume>7</volume>:<fpage>30</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23118817</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>VV</given-names></name>, <name><surname>Archer</surname><given-names>SL</given-names></name>, <name><surname>Badesch</surname><given-names>DB</given-names></name><etal/></person-group>
<article-title>ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association</article-title>. <source>J Am Coll Cardiol</source>
<year>2009</year>;<volume>53</volume>:<fpage>1573</fpage>&#x02013;<lpage>619</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jacc.2009.01.004">doi:10.1016/j.jacc.2009.01.004</ext-link><pub-id pub-id-type="pmid">19389575</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupi</surname><given-names>AM</given-names></name>, <name><surname>Steen</surname><given-names>VD</given-names></name>, <name><surname>Owens</surname><given-names>GR</given-names></name><etal/></person-group>
<article-title>Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis</article-title>. <source>Arthritis Rheum</source>
<year>1986</year>;<volume>29</volume>:<fpage>515</fpage>&#x02013;<lpage>24</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.1780290409">doi:10.1002/art.1780290409</ext-link><pub-id pub-id-type="pmid">3707629</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachulla</surname><given-names>E</given-names></name>, <name><surname>Gressin</surname><given-names>V</given-names></name>, <name><surname>Guillevin</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study</article-title>. <source>Arthritis Rheum</source>
<year>2005</year>;<volume>52</volume>:<fpage>3792</fpage>&#x02013;<lpage>800</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.21433">doi:10.1002/art.21433</ext-link><pub-id pub-id-type="pmid">16320330</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steen</surname><given-names>V</given-names></name>, <name><surname>Medsger</surname><given-names>TA</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement</article-title>. <source>Arthritis Rheum</source>
<year>2003</year>;<volume>48</volume>:<fpage>516</fpage>&#x02013;<lpage>22</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.10775">doi:10.1002/art.10775</ext-link><pub-id pub-id-type="pmid">12571862</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeper</surname><given-names>MM</given-names></name>, <name><surname>Bogaard</surname><given-names>HJ</given-names></name>, <name><surname>Condliffe</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Definitions and diagnosis of pulmonary hypertension</article-title>. <source>J Am Coll Cardiol</source>
<year>2013</year>;<volume>62</volume>(Suppl <issue>25</issue>):<fpage>D42</fpage>&#x02013;<lpage>50</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jacc.2013.10.032">doi:10.1016/j.jacc.2013.10.032</ext-link><pub-id pub-id-type="pmid">24355641</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaine</surname><given-names>SP</given-names></name>, <name><surname>Rubin</surname><given-names>LJ</given-names></name></person-group>
<article-title>Primary pulmonary hypertension</article-title>. <source>Lancet</source>
<year>1998</year>;<volume>352</volume>:<fpage>719</fpage>&#x02013;<lpage>25</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(98)02111-4">doi:10.1016/S0140-6736(98)02111-4</ext-link><pub-id pub-id-type="pmid">9729004</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunig</surname><given-names>E</given-names></name>, <name><surname>Ehlken</surname><given-names>N</given-names></name>, <name><surname>Ghofrani</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension</article-title>. <source>Respiration</source>
<year>2011</year>;<volume>81</volume>:<fpage>394</fpage>&#x02013;<lpage>401</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000322475">doi:10.1159/000322475</ext-link><pub-id pub-id-type="pmid">21311162</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mereles</surname><given-names>D</given-names></name>, <name><surname>Ehlken</surname><given-names>N</given-names></name>, <name><surname>Kreuscher</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension</article-title>. <source>Circulation</source>
<year>2006</year>;<volume>114</volume>:<fpage>1482</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.106.618397">doi:10.1161/CIRCULATIONAHA.106.618397</ext-link><pub-id pub-id-type="pmid">16982941</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name>, <name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group>
<article-title>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</article-title>. <source>Med Care</source>
<year>1992</year>;<volume>30</volume>:<fpage>473</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">1593914</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>KS</given-names></name>, <name><surname>Wong</surname><given-names>PK</given-names></name>, <name><surname>Faux</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>The benefit of exercise training in pulmonary hypertension: a clinical review</article-title>. <source>Intern Med J</source>
<year>2016</year>
<comment>doi:10.1111/imj.13159 [Epub ahead of print 24 Jun 2016].</comment><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/imj.13159">doi:10.1111/imj.13159</ext-link></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunig</surname><given-names>E</given-names></name>, <name><surname>Lichtblau</surname><given-names>M</given-names></name>, <name><surname>Ehlken</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Safety and efficacy of exercise training in various forms of pulmonary hypertension</article-title>. <source>Eur Respir J</source>
<year>2012</year>;<volume>40</volume>:<fpage>84</fpage>&#x02013;<lpage>92</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.00123711">doi:10.1183/09031936.00123711</ext-link><pub-id pub-id-type="pmid">22323570</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunig</surname><given-names>E</given-names></name>, <name><surname>Maier</surname><given-names>F</given-names></name>, <name><surname>Ehlken</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Exercise training in pulmonary arterial hypertension associated with connective tissue diseases</article-title>. <source>Arthritis Res Ther</source>
<year>2012</year>;<volume>14</volume>:<fpage>R148</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/ar3883">doi:10.1186/ar3883</ext-link><pub-id pub-id-type="pmid">22709477</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagel</surname><given-names>C</given-names></name>, <name><surname>Prange</surname><given-names>F</given-names></name>, <name><surname>Guth</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension</article-title>. <source>PLoS ONE</source>
<year>2012</year>;<volume>7</volume>:<fpage>e41603</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0041603">doi:10.1371/journal.pone.0041603</ext-link><pub-id pub-id-type="pmid">22848542</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker-Grunig</surname><given-names>T</given-names></name>, <name><surname>Klose</surname><given-names>H</given-names></name>, <name><surname>Ehlken</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease</article-title>. <source>Int J Cardiol</source>
<year>2013</year>;<volume>168</volume>:<fpage>375</fpage>&#x02013;<lpage>81</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijcard.2012.09.036">doi:10.1016/j.ijcard.2012.09.036</ext-link><pub-id pub-id-type="pmid">23041100</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehlken</surname><given-names>N</given-names></name>, <name><surname>Lichtblau</surname><given-names>M</given-names></name>, <name><surname>Klose</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial</article-title>. <source>Eur Heart J</source>
<year>2016</year>;<volume>37</volume>:<fpage>35</fpage>&#x02013;<lpage>44</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehv337">doi:10.1093/eurheartj/ehv337</ext-link><pub-id pub-id-type="pmid">26231884</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>S</given-names></name>, <name><surname>Fink</surname><given-names>C</given-names></name>, <name><surname>Risse</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension</article-title>. <source>Eur Radiol</source>
<year>2013</year>;<volume>23</volume>:<fpage>324</fpage>&#x02013;<lpage>31</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00330-012-2606-z">doi:10.1007/s00330-012-2606-z</ext-link><pub-id pub-id-type="pmid">22886553</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabitz</surname><given-names>HJ</given-names></name>, <name><surname>Bremer</surname><given-names>HC</given-names></name>, <name><surname>Schwoerer</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension</article-title>. <source>Lung</source>
<year>2014</year>;<volume>192</volume>:<fpage>321</fpage>&#x02013;<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00408-013-9542-9">doi:10.1007/s00408-013-9542-9</ext-link><pub-id pub-id-type="pmid">24338088</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="other"><collab>Alison Jea</collab>. <comment>The Pulmonary Rehabilitation Toolkit on behalf of the Australian Lung Foundation (2009)</comment>
<year>2009</year>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.pulmonaryrehab.com.au">http://www.pulmonaryrehab.com.au</ext-link></comment>.</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="other"><collab>Heart Foundation A</collab>. <comment>Recommended framework for cardiac rehabilitation &#x02018;04</comment>
<year>2004</year> (<comment><ext-link ext-link-type="uri" xlink:href="http://www.heartfoundation.org.au/SiteCollectionDocuments/Recommended-framework.pdf">http://www.heartfoundation.org.au/SiteCollectionDocuments/Recommended-framework.pdf</ext-link></comment>).</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mainguy</surname><given-names>V</given-names></name>, <name><surname>Maltais</surname><given-names>F</given-names></name>, <name><surname>Saey</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension</article-title>. <source>J Cardiopulm Rehabil Prev</source>
<year>2010</year>;<volume>30</volume>:<fpage>319</fpage>&#x02013;<lpage>23</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/HCR.0b013e3181d6f962">doi:10.1097/HCR.0b013e3181d6f962</ext-link><pub-id pub-id-type="pmid">20410828</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>BD</given-names></name>, <name><surname>Kassirer</surname><given-names>M</given-names></name>, <name><surname>Weiss</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension</article-title>. <source>Jf Cardiac Failure</source>
<year>2011</year>;<volume>17</volume>:<fpage>196</fpage>&#x02013;<lpage>200</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cardfail.2010.10.004">doi:10.1016/j.cardfail.2010.10.004</ext-link></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>L</given-names></name>, <name><surname>Chin</surname><given-names>LM</given-names></name>, <name><surname>Kennedy</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension</article-title>. <source>Chest</source>
<year>2013</year>;<volume>143</volume>:<fpage>333</fpage>&#x02013;<lpage>43</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.12-0993">doi:10.1378/chest.12-0993</ext-link><pub-id pub-id-type="pmid">22922554</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>AA</given-names></name>, <name><surname>Chin</surname><given-names>LM</given-names></name>, <name><surname>Keyser</surname><given-names>RE</given-names></name><etal/></person-group>
<article-title>Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension</article-title>. <source>Respir Med</source>
<year>2013</year>;<volume>107</volume>:<fpage>778</fpage>&#x02013;<lpage>84</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2013.02.006">doi:10.1016/j.rmed.2013.02.006</ext-link><pub-id pub-id-type="pmid">23478192</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>T</given-names></name>, <name><surname>Terada</surname><given-names>J</given-names></name>, <name><surname>Tanabe</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Home-based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: a preliminary study</article-title>. <source>Respir Investig</source>
<year>2014</year>;<volume>52</volume>:<fpage>357</fpage>&#x02013;<lpage>64</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.resinv.2014.07.002">doi:10.1016/j.resinv.2014.07.002</ext-link></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saglam</surname><given-names>M</given-names></name>, <name><surname>Arikan</surname><given-names>H</given-names></name>, <name><surname>Vardar-Yagli</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Inspiratory muscle training in pulmonary arterial hypertension</article-title>. <source>J Cardiopulm Rehabil Prev</source>
<year>2015</year>;<volume>35</volume>:<fpage>198</fpage>&#x02013;<lpage>206</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/HCR.0000000000000117">doi:10.1097/HCR.0000000000000117</ext-link><pub-id pub-id-type="pmid">25909652</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuman</surname><given-names>A</given-names></name>, <name><surname>Gunnbj&#x000f6;rnsdottir</surname><given-names>M</given-names></name>, <name><surname>Tuns&#x000e4;ter</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Dyspnea in relation to symptoms of anxiety and depression: a prospective population study</article-title>. <source>Respir Med</source>
<year>2006</year>;<volume>100</volume>:<fpage>1843</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2006.01.016">doi:10.1016/j.rmed.2006.01.016</ext-link><pub-id pub-id-type="pmid">16516455</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gali&#x000e8;</surname><given-names>N</given-names></name>, <name><surname>Hoeper</surname><given-names>MM</given-names></name>, <name><surname>Humbert</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Heart J</source>
<year>2009</year>;<volume>30</volume>:<fpage>2493</fpage>&#x02013;<lpage>537</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehp297">doi:10.1093/eurheartj/ehp297</ext-link><pub-id pub-id-type="pmid">19713419</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>, <name><surname>Moher</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title>. <source>J Clin Epidemiol</source>
<year>2010</year>;<volume>63</volume>:<fpage>834</fpage>&#x02013;<lpage>40</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jclinepi.2010.02.005">doi:10.1016/j.jclinepi.2010.02.005</ext-link><pub-id pub-id-type="pmid">20346629</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saghaei MaS</surname><given-names>S</given-names></name></person-group>
<article-title>Implementation of an open-source customizable minimization program for allocation of patients to parallel groups in clinical trials</article-title><source>. <italic>J Biomed Sci Eng</italic></source>
<year>2011</year>;<volume>4</volume>:<fpage>734</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4236/jbise.2011.411090:734-39">doi:10.4236/jbise.2011.411090:734-39</ext-link></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonk-Noordegraaf</surname><given-names>A</given-names></name>, <name><surname>Souza</surname><given-names>R</given-names></name></person-group>
<article-title>Cardiac magnetic resonance imaging: what can it add to our knowledge of the right ventricle in pulmonary arterial hypertension?</article-title>
<source>Am J Cardiol</source>
<year>2012</year>;<volume>110</volume>(Suppl <issue>6</issue>):<fpage>25s</fpage>&#x02013;<lpage>31s</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjcard.2012.06.013">doi:10.1016/j.amjcard.2012.06.013</ext-link><pub-id pub-id-type="pmid">22921028</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellman</surname><given-names>P</given-names></name>, <name><surname>Arai</surname><given-names>AE</given-names></name>, <name><surname>McVeigh</surname><given-names>ER</given-names></name><etal/></person-group>
<article-title>Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement</article-title>. <source>Magn Reson Med</source>
<year>2002</year>;<volume>47</volume>:<fpage>372</fpage>&#x02013;<lpage>83</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mrm.10051">doi:10.1002/mrm.10051</ext-link><pub-id pub-id-type="pmid">11810682</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>CJ</given-names></name>, <name><surname>Ntusi</surname><given-names>N</given-names></name>, <name><surname>Suttie</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients</article-title>. <source>Circulation</source>
<year>2013</year>;<volume>128</volume>:<fpage>
814</fpage>&#x02013;<lpage>22</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.113.001719">doi:10.1161/CIRCULATIONAHA.113.001719</ext-link><pub-id pub-id-type="pmid">23817574</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>CJ</given-names></name>, <name><surname>Montgomery</surname><given-names>HE</given-names></name>, <name><surname>Murray</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Cardiac response to hypobaric hypoxia: persistent changes in cardiac mass, function, and energy metabolism after a trek to Mt. Everest Base Camp</article-title>. <source>FASEB J</source>
<year>2011</year>;<volume>25</volume>:<fpage>792</fpage>&#x02013;<lpage>6</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1096/fj.10-172999">doi:10.1096/fj.10-172999</ext-link><pub-id pub-id-type="pmid">20978235</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagiotou</surname><given-names>M</given-names></name>, <name><surname>Peacock</surname><given-names>AJ</given-names></name>, <name><surname>Johnson</surname><given-names>MK</given-names></name></person-group>
<article-title>Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?</article-title>
<source>Pulm Circ</source>
<year>2015</year>;<volume>5</volume>:<fpage>424</fpage>&#x02013;<lpage>34</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/682431">doi:10.1086/682431</ext-link><pub-id pub-id-type="pmid">26401245</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batt</surname><given-names>J</given-names></name>, <name><surname>Ahmed</surname><given-names>SS</given-names></name>, <name><surname>Correa</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Skeletal muscle dysfunction in idiopathic pulmonary arterial hypertension</article-title>. <source>Am J Respir Cell Mol Biol</source>
<year>2014</year>;<volume>50</volume>:<fpage>74</fpage>&#x02013;<lpage>86</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1165/rcmb.2012-0506OC">doi:10.1165/rcmb.2012-0506OC</ext-link><pub-id pub-id-type="pmid">23972212</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breda</surname><given-names>AP</given-names></name>, <name><surname>Pereira de Albuquerque</surname><given-names>AL</given-names></name>, <name><surname>Jardim</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Skeletal muscle abnormalities in pulmonary arterial hypertension</article-title>. <source>PLoS ONE</source>
<year>2014</year>;<volume>9</volume>:<fpage>e114101</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0114101">doi:10.1371/journal.pone.0114101</ext-link><pub-id pub-id-type="pmid">25460348</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimopoulos</surname><given-names>S</given-names></name>, <name><surname>Tzanis</surname><given-names>G</given-names></name>, <name><surname>Manetos</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Peripheral muscle microcirculatory alterations in patients with pulmonary arterial hypertension: a pilot study</article-title>. <source>Respir Care</source>
<year>2013</year>;<volume>58</volume>:<fpage>2134</fpage>&#x02013;<lpage>41</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4187/respcare.02113">doi:10.4187/respcare.02113</ext-link><pub-id pub-id-type="pmid">23716709</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mainguy</surname><given-names>V</given-names></name>, <name><surname>Maltais</surname><given-names>F</given-names></name>, <name><surname>Saey</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension</article-title>. <source>Thorax</source>
<year>2010</year>;<volume>65</volume>:<fpage>113</fpage>&#x02013;<lpage>17</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thx.2009.117168">doi:10.1136/thx.2009.117168</ext-link><pub-id pub-id-type="pmid">19720606</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>DP</given-names></name>, <name><surname>Teo</surname><given-names>KK</given-names></name>, <name><surname>Rangarajan</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study</article-title>. <source>Lancet</source>
<year>2015</year>;<volume>386</volume>:<fpage>266</fpage>&#x02013;<lpage>73</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(14)62000-6">doi:10.1016/S0140-6736(14)62000-6</ext-link><pub-id pub-id-type="pmid">25982160</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>A</given-names></name>, <name><surname>Garg</surname><given-names>S</given-names></name>, <name><surname>Khunger</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis</article-title>. <source>Circ Heart Fail</source>
<year>2015</year>;<volume>8</volume>:<fpage>1032</fpage>&#x02013;<lpage>43</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002130">doi:10.1161/CIRCHEARTFAILURE.115.002130</ext-link><pub-id pub-id-type="pmid">26185169</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buys</surname><given-names>R</given-names></name>, <name><surname>Avila</surname><given-names>A</given-names></name>, <name><surname>Cornelissen</surname><given-names>VA</given-names></name></person-group>
<article-title>Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials</article-title>. <source>BMC Pulm Med</source>
<year>2015</year>;<volume>15</volume>:<fpage>40</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12890-015-0031-1">doi:10.1186/s12890-015-0031-1</ext-link><pub-id pub-id-type="pmid">25896259</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>AE</given-names></name>, <name><surname>Spruit</surname><given-names>MA</given-names></name>, <name><surname>Troosters</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>An official European respiratory society/American thoracic society technical standard: field walking tests in chronic respiratory disease</article-title>. <source>Eur Respir J</source>
<year>2014</year>;<volume>44</volume>:<fpage>1428</fpage>&#x02013;<lpage>46</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.00150314">doi:10.1183/09031936.00150314</ext-link><pub-id pub-id-type="pmid">25359355</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f6;we</surname><given-names>B</given-names></name>, <name><surname>Gr&#x000e4;fe</surname><given-names>K</given-names></name>, <name><surname>Ufer</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Anxiety and depression in patients with pulmonary hypertension</article-title>. <source>Psychosom Med</source>
<year>2004</year>;<volume>66</volume>:<fpage>831</fpage>&#x02013;<lpage>6</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.psy.0000145593.37594.39">doi:10.1097/01.psy.0000145593.37594.39</ext-link><pub-id pub-id-type="pmid">15564346</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harzheim</surname><given-names>D</given-names></name>, <name><surname>Klose</surname><given-names>H</given-names></name>, <name><surname>Pinado</surname><given-names>FP</given-names></name><etal/></person-group>
<article-title>Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension</article-title>. <source>Respir Res</source>
<year>2013</year>;<volume>14</volume>:<fpage>104</fpage>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1465-9921-14-104">doi:10.1186/1465-9921-14-104</ext-link><pub-id pub-id-type="pmid">24107187</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafazand</surname><given-names>S</given-names></name>, <name><surname>Goldstein</surname><given-names>MK</given-names></name>, <name><surname>Doyle</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Health-related quality of life in patients with pulmonary arterial hypertension</article-title>. <source>Chest</source>
<year>2004</year>;<volume>126</volume>:<fpage>1452</fpage>&#x02013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.126.5.1452">doi:10.1378/chest.126.5.1452</ext-link><pub-id pub-id-type="pmid">15539712</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>C</given-names></name></person-group>
<article-title>The Lawton instrumental activities of daily living scale</article-title>. <source>Am J Nurs</source>
<year>2008</year>;<volume>108</volume>:<fpage>52</fpage>&#x02013;<lpage>62</lpage>; <comment>quiz 62-3</comment>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.NAJ.0000314810.46029.74">doi:10.1097/01.NAJ.0000314810.46029.74</ext-link></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>SP</given-names></name>, <name><surname>Doughty</surname><given-names>N</given-names></name>, <name><surname>Meads</surname><given-names>DM</given-names></name><etal/></person-group>
<article-title>The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension</article-title>. <source>Qual Life Res</source>
<year>2006</year>;<volume>15</volume>:<fpage>103</fpage>&#x02013;<lpage>15</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11136-005-3513-4">doi:10.1007/s11136-005-3513-4</ext-link><pub-id pub-id-type="pmid">16411035</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganderton</surname><given-names>L</given-names></name>, <name><surname>Jenkins</surname><given-names>S</given-names></name>, <name><surname>McKenna</surname><given-names>SP</given-names></name><etal/></person-group>
<article-title>Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population</article-title>. <source>Respirology</source>
<year>2011</year>;<volume>16</volume>:<fpage>1235</fpage>&#x02013;<lpage>40</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1440-1843.2011.02030.x">doi:10.1111/j.1440-1843.2011.02030.x</ext-link><pub-id pub-id-type="pmid">21810146</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>C</given-names></name></person-group>
<article-title>The Lawton Instrumental Activities of Daily Living (IADL) Scale</article-title>. <source>Medsurg Nurs</source>
<year>2009</year>;<volume>18</volume>:<fpage>315</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">19927971</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>JD</given-names></name>, <name><surname>Crawford</surname><given-names>JR</given-names></name></person-group>
<article-title>The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample</article-title>. <source>Br J Clin Psychol</source>
<year>2005</year>;<volume>44</volume>(Pt <issue>2</issue>):<fpage>227</fpage>&#x02013;<lpage>39</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1348/014466505X29657">doi:10.1348/014466505X29657</ext-link><pub-id pub-id-type="pmid">16004657</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name>, <name><surname>Nishikimi</surname><given-names>T</given-names></name>, <name><surname>Uematsu</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension</article-title>. <source>Circulation</source>
<year>2000</year>;<volume>102</volume>:<fpage>865</fpage>&#x02013;<lpage>70</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.CIR.102.8.865">doi:10.1161/01.CIR.102.8.865</ext-link><pub-id pub-id-type="pmid">10952954</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heresi</surname><given-names>GA</given-names></name>, <name><surname>Aytekin</surname><given-names>M</given-names></name>, <name><surname>Hammel</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension</article-title>. <source>Eur Respir J</source>
<year>2014</year>;<volume>43</volume>:<fpage>912</fpage>&#x02013;<lpage>14</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09031936.00164713">doi:10.1183/09031936.00164713</ext-link><pub-id pub-id-type="pmid">24136333</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>R</given-names></name>, <name><surname>Jardim</surname><given-names>C</given-names></name>, <name><surname>Julio Cesar Fernandes</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension</article-title>. <source>Respir Med</source>
<year>2007</year>;<volume>101</volume>:<fpage>69</fpage>&#x02013;<lpage>75</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2006.04.014">doi:10.1016/j.rmed.2006.04.014</ext-link><pub-id pub-id-type="pmid">16781131</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fijalkowska</surname><given-names>A</given-names></name>, <name><surname>Kurzyna</surname><given-names>M</given-names></name>, <name><surname>Torbicki</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension</article-title>. <source>Chest</source>
<year>2006</year>;<volume>129</volume>:<fpage>1313</fpage>&#x02013;<lpage>21</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1378/chest.129.5.1313">doi:10.1378/chest.129.5.1313</ext-link><pub-id pub-id-type="pmid">16685024</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Man</surname><given-names>FS</given-names></name>, <name><surname>van Hees</surname><given-names>HW</given-names></name>, <name><surname>Handoko</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Diaphragm muscle fiber weakness in pulmonary hypertension</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2011</year>;<volume>183</volume>:<fpage>1411</fpage>&#x02013;<lpage>18</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201003-0354OC">doi:10.1164/rccm.201003-0354OC</ext-link><pub-id pub-id-type="pmid">21131469</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabitz</surname><given-names>HJ</given-names></name>, <name><surname>Schwoerer</surname><given-names>A</given-names></name>, <name><surname>Bremer</surname><given-names>HC</given-names></name><etal/></person-group>
<article-title>Impairment of respiratory muscle function in pulmonary hypertension</article-title>. <source>Clin Sci</source>
<year>2008</year>;<volume>114</volume>:<fpage>165</fpage>&#x02013;<lpage>71</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/CS20070238">doi:10.1042/CS20070238</ext-link><pub-id pub-id-type="pmid">17764445</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><collab>American Thoracic Society/European Respiratory Society</collab>. <article-title>ATS/ERS Statement on respiratory muscle testing</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2002</year>;<volume>166</volume>:<fpage>518</fpage>&#x02013;<lpage>624</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.166.4.518">doi:10.1164/rccm.166.4.518</ext-link><pub-id pub-id-type="pmid">12186831</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherr</surname><given-names>J</given-names></name>, <name><surname>Wolfarth</surname><given-names>B</given-names></name>, <name><surname>Christle</surname><given-names>JW</given-names></name><etal/></person-group>
<article-title>Associations between Borg's rating of perceived exertion and physiological measures of exercise intensity</article-title>. <source>Eur J Appl Physiol</source>
<year>2013</year>;<volume>113</volume>:<fpage>147</fpage>&#x02013;<lpage>55</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00421-012-2421-x">doi:10.1007/s00421-012-2421-x</ext-link><pub-id pub-id-type="pmid">22615009</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>AE</given-names></name>, <name><surname>Wadell</surname><given-names>K</given-names></name>, <name><surname>Spruit</surname><given-names>MA</given-names></name></person-group>
<article-title>How to adapt the pulmonary rehabilitation programme to patients with chronic respiratory disease other than COPD</article-title>. <source>Eur Respir Rev</source>
<year>2013</year>;<volume>22</volume>:<fpage>577</fpage>&#x02013;<lpage>86</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09059180.00005613">doi:10.1183/09059180.00005613</ext-link><pub-id pub-id-type="pmid">24293474</pub-id></mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruit</surname><given-names>MA</given-names></name>, <name><surname>Singh</surname><given-names>SJ</given-names></name>, <name><surname>Garvey</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>An official American Thoracic Society/European respiratory society statement: key concepts and advances in pulmonary rehabilitation</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2013</year>;<volume>188</volume>:<fpage>e13</fpage>&#x02013;<lpage>64</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.201309-1634ST">doi:10.1164/rccm.201309-1634ST</ext-link><pub-id pub-id-type="pmid">24127811</pub-id></mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>K</given-names></name>, <name><surname>Cecins</surname><given-names>NM</given-names></name>, <name><surname>Eastwood</surname><given-names>PR</given-names></name><etal/></person-group>
<article-title>Inspiratory muscle training for patients with chronic obstructive pulmonary disease: a practical guide for clinicians</article-title>. <source>Arch Phys Med Rehabil</source>
<year>2010</year>;<volume>91</volume>:<fpage>1466</fpage>&#x02013;<lpage>70</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.apmr.2010.06.010">doi:10.1016/j.apmr.2010.06.010</ext-link><pub-id pub-id-type="pmid">20801269</pub-id></mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahalin</surname><given-names>LP</given-names></name>, <name><surname>Arena</surname><given-names>RA</given-names></name></person-group>
<article-title>Breathing exercises and inspiratory muscle training in heart failure</article-title>. <source>Heart Fail Clin</source>
<year>2015</year>;<volume>11</volume>:<fpage>149</fpage>&#x02013;<lpage>72</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.hfc.2014.09.002">doi:10.1016/j.hfc.2014.09.002</ext-link><pub-id pub-id-type="pmid">25432483</pub-id></mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>WJ</given-names></name>, <name><surname>Adams</surname><given-names>K</given-names></name>, <name><surname>Cafarelli</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>American college of sports medicine position stand. Progression models in resistance training for healthy adults</article-title>. <source>Med Sci Sports Exerc</source>
<year>2002</year>;<volume>34</volume>:<fpage>364</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">11828249</pub-id></mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gloeckl</surname><given-names>R</given-names></name>, <name><surname>Marinov</surname><given-names>B</given-names></name>, <name><surname>Pitta</surname><given-names>F</given-names></name></person-group>
<article-title>Practical recommendations for exercise training in patients with COPD</article-title>. <source>Eur Respir Rev</source>
<year>2013</year>;<volume>22</volume>:<fpage>178</fpage>&#x02013;<lpage>86</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1183/09059180.00000513">doi:10.1183/09059180.00000513</ext-link><pub-id pub-id-type="pmid">23728873</pub-id></mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="other"><collab>CRUFAD CRUFAD, St Vincent's Hospital Sydney, Australia</collab>. <comment>Anxiety and Panic Disorder. Patient Treatment Manual</comment>
<year>2010</year>
<comment>https://crufad.org/images/stories/pdf/manuals/crufad_Panicmanual.pdf (accessed 14 Mar 2016).</comment></mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Sage</surname><given-names>N</given-names></name>, <name><surname>Sowden</surname><given-names>M</given-names></name>, <name><surname>Chorlton</surname><given-names>E</given-names></name><etal/></person-group>
<source>CBT for chronic illness and palliative care: a workbook and toolkit</source>. <conf-loc>England</conf-loc>: <publisher-name>John Wiley and Sons</publisher-name>, <year>2008</year>.</mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>E.</given-names></name></person-group>
<source>Progressive relaxation</source>. <publisher-loc>Chicago, IL, USA</publisher-loc>: <publisher-name>University of Chicago Press</publisher-name>, <year>1938</year>.</mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="other"><collab>NHMRC</collab>. <comment>National Statement on Ethical Conduct in Human Research (2007)&#x02014;Updated March 2014</comment>
<year>2007</year>.</mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawut</surname><given-names>SM</given-names></name>, <name><surname>Horn</surname><given-names>EM</given-names></name>, <name><surname>Berekashvili</surname><given-names>KK</given-names></name><etal/></person-group>
<article-title>New predictors of outcome in idiopathic pulmonary arterial hypertension</article-title>. <source>Am J Cardiol</source>
<year>2005</year>;<volume>95</volume>:<fpage>199</fpage>&#x02013;<lpage>203</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjcard.2004.09.006">doi:10.1016/j.amjcard.2004.09.006</ext-link><pub-id pub-id-type="pmid">15642552</pub-id></mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addetia</surname><given-names>K</given-names></name>, <name><surname>Bhave</surname><given-names>NM</given-names></name>, <name><surname>Tabit</surname><given-names>CE</given-names></name><etal/></person-group>
<article-title>Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points</article-title>. <source>Circ Cardiovasc Imaging</source>
<year>2014</year>;<volume>7</volume>:<fpage>115</fpage>&#x02013;<lpage>24</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCIMAGING.113.000932">doi:10.1161/CIRCIMAGING.113.000932</ext-link><pub-id pub-id-type="pmid">24192452</pub-id></mixed-citation></ref><ref id="R76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradlow</surname><given-names>WM</given-names></name>, <name><surname>Hughes</surname><given-names>ML</given-names></name>, <name><surname>Keenan</surname><given-names>NG</given-names></name><etal/></person-group>
<article-title>Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size</article-title>. <source>J Magn Reson Imaging</source>
<year>2010</year>;<volume>31</volume>:<fpage>117</fpage>&#x02013;<lpage>24</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jmri.22011">doi:10.1002/jmri.22011</ext-link><pub-id pub-id-type="pmid">20027579</pub-id></mixed-citation></ref><ref id="R77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>B</given-names></name></person-group>
<article-title>How to calculate sample size in randomized controlled trial?</article-title>
<source>J Thorac Dis</source>
<year>2009</year>;<volume>1</volume>:<fpage>51</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">22263004</pub-id></mixed-citation></ref></ref-list></back></article>